Non-Small Cell Lung Cancer Market in 7MM is expected to change in the study period 2019-2032

The Non-Small Cell Lung Cancer Market report provides emerging drugs, Non-Small Cell Lung Cancer market share of the individual cancer types, current and forecasted Non-Small Cell Lung Cancer market size from 2019 to 2032 segmented by seven major markets. The Report also covers current M Non-Small Cell Lung Cancer unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Key takeaways from the Non-Small Cell Lung Cancer Market Research Report

• As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017. These cases are expected to grow with a significant CAGR in the study period 2017-2030.
• As per the DelveInsight estimates, the total incident cases of NSCLC patients by histology in the 7MM were observed to be 142,566, 228,106, 57,027, and 57,027 cases of squamous cell carcinoma, adenocarcinoma, large cell carcinoma, and others in the year 2017. These cases are expected to grow with a significant CAGR in the study period 2017-2030.
• As per the DelveInsight estimates, the total diagnosed cases of NSCLC patients by stages in the 7MM were observed to be 86,590, 31,552, 56,297, 65,410, and 244,876 cases of stage I, stage II, stage IIIA, stage IIIB, and stage IV in the year 2017.
• As per the DelveInsight estimates, the total diagnosed cases of NSCLC patients by stages in Germany were observed to be 9,546, 4,658, 7,346, 11,392, and 23,177 cases of stage I, stage II, stage IIIA, stage IIIB, and stage IV in the year 2017. These cases are expected to grow with a significant CAGR in the study period 2017-2030.
• As per the DelveInsight estimates, the total NSCLC cases of patients by genetic mutation/biomarkers in the United States were observed to be 89,597, 37,370, 50,393, 8,449, 12,665, 8,979, 7,202, and 2,136 cases of PD-L1, EGFR, KRAS, ALK, PI3KCA, BRAF, MET, and ROS-1 in the year 2017. These cases are expected to grow with a significant CAGR in the study period 2017-2030.

To explore more information on the latest breakthroughs in the Non-Small Cell Lung Cancer Treatment Landscape, visit Non-Small Cell Lung Cancer Market Size @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Non-Small Cell Lung Cancer Overview
NSCLC can be defined as any type of epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas, and sarcomatoid carcinomas. NSCLC can be located in the mid-chest, but it is often also found in other parts of the lung too. Even though NSCLCs are associated with cigarette smoking, adenocarcinomas may also be found in patients who have never smoked. Also, itis relatively insensitive to chemotherapy and radiation therapy in comparison with SCLC.

Non-Small Cell Lung Cancer Epidemiology Segmentation in the 7MM
• Total Non-Small Cell Lung Cancer Incident cases patients
• Total Non-Small Cell Lung Cancer Incident cases by Histology
• Total Non-Small Cell Lung Cancer Diagnosed cases patients by Stages
• Total Non-Small Cell Lung Cancer cases of patients by Genetic mutation/Biomarkers
• Total Non-Small Cell Lung Cancer Treated Cases by Line of Therapies

Find new updates of the Non-Small Cell Lung Cancer Market Trends of the report, click here -Small Cell Lung Cancer Market Forecast @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Non-Small Cell Lung Cancer Approved Drug
1. Rozlytrek (Entrectinib): Hoffmann-La Roche (Genentech)
2. Imfinzi (Durvalumab): AstraZeneca
3. Opdivo (Nivolumab): Bristol-Myers Squibb
4. Tecentriq (Atezolizumab): Hoffmann-La Roche
5. Keytruda (Pembrolizumab): Merck
6. Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib): Novartis
7. Tagrisso (Osimertinib): AstraZeneca
8. Lorbrena/Lorviqua (Lorlatinib): Pfizer
9. Vizimpro (Dacomitinib): Pfizer
10. Alunbrig (Brigatinib): Takeda Pharmaceuticals
11. Alecensa (Alectinib): Hoffmann-La Roche
12. Vitrakvi (Larotrectinib): Bayer Healthcare
13. Portrazza (Necitumumab): Eli Lilly and Company

Non-Small Cell Lung Cancer Emerging Drugs

1. Nazartinib/EGF816: Novartis Pharmaceuticals
2. Capmatinib/INC280: Novartis Pharmaceuticals
3. Telisotuzumab Vedotin: AbbVie
4. JNJ-61186372/JNJ-6372: Janssen Pharmaceuticals
5. Ensartinib/X-396: Xcovery
6. Selpercatinib (LY3527723/LOXO-292): Eli Lilly and Company
7. SAR408701: Sanofi
8. Braftovi/encorafinib + Mektovi/binimetinib: Pfizer
9. PADCEV (enfortumab vedotin/ASG-22ME): Astellas Pharma/Seattle Genetics
10. TAK-788: Takeda Pharmaceuticals
11. Canakinumab/(ACZ885): Novartis
12. BAVENCIO (Avelumab): Merck/Pfizer
13. Veliparib: AbbVie
14. Sitravatinib (MGCD516): Mirati Therapeutics/Bristol-Myers Squibb/Beigene
15. M7824: Merck/GlaxoSmithKline
16. AMG 510: Amgen
17. INCMGA00012 (MGA012): Incyte Corporation
18. Romiplostim: Amgen
19. TEPMETKO (tepotinib): Merck

Non-Small Cell Lung Cancer Market Outlook
Typically, chemotherapy, targeted treatments, and immunotherapy-alone or in combination-are used to treat lung cancer. Besides, pharmacological treatment choices, surgery, and radiation are also frequently opted. When the patient is in the initial stages, the tumor is usually resectable. Most stage I and stage II NSCLC are treated with surgery to remove the tumor.



To recommend a treatment option to a patient of Non-Small Cell Lung Cancer, several key factors are taken into consideration, such as age of the patient, previous medical history, health status, and smoking history. Along with these, another essential factor to consider is the stage of cancer at the time of diagnosis. Staging is usually carried out twice: after clinical and radiological examinations; and after surgery, in the case of the surgically resected tumor. Furthermore, biological testing of the tumor is also crucial to understand the presence of specific mutations.

Get to know more about the Non-Small Cell Lung Cancer Recent News, Updates of the Non-Small Cell Lung Cancer Market report, click here Non-Small Cell Lung Cancer Ongoing Clinical Trials Analysis @ https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Non-Small Cell Lung Cancer Treatment Market
The main choice of treatment for cancer, before the discovery of targeted therapies was chemotherapy. Chemotherapy works by disrupting the way that cancer cells grow and divide. However, these drugs can also affect normal cells. Chemotherapy can be given before or after surgery for NSCLC. Some people have chemotherapy at the same time as radiotherapy this is called chemoradiotherapy. Chemotherapy may be given to try to cure cancer or to prolong life and control symptoms (palliative care). One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments. Unlike chemotherapy drugs, which cannot tell the difference between normal cells and cancer cells, targeted therapies are designed to attack cancer cells specifically by attaching to or blocking targets that appear on the surfaces of those cells. People who have advanced lung cancer with certain molecular biomarkers may receive treatment with a targeted drug alone or in combination with chemotherapy.

Non-Small Cell Lung Cancer Pipeline Therapies and Companies
1. Nazartinib/EGF816: Novartis Pharmaceuticals
2. Capmatinib/INC280: Novartis Pharmaceuticals
3. Telisotuzumab Vedotin: AbbVie
4. JNJ-61186372/JNJ-6372: Janssen Pharmaceuticals
5. Ensartinib/X-396: Xcovery
6. Selpercatinib (LY3527723/LOXO-292): Eli Lilly and Company
7. SAR408701: Sanofi
8. Braftovi/encorafinib + Mektovi/binimetinib: Pfizer
9. PADCEV (enfortumab vedotin/ASG-22ME): Astellas Pharma/Seattle Genetics
10. TAK-788: Takeda Pharmaceuticals
11. Canakinumab/(ACZ885): Novartis
12. BAVENCIO (Avelumab): Merck/Pfizer
13. Veliparib: AbbVie
14. Sitravatinib (MGCD516): Mirati Therapeutics/Bristol-Myers Squibb/Beigene
15. M7824: Merck/GlaxoSmithKline
16. AMG 510: Amgen
17. INCMGA00012 (MGA012): Incyte Corporation
18. Romiplostim: Amgen
19. TEPMETKO (tepotinib): Merck

Discover more information on the Non-Small Cell Lung Cancer Market Dynamics. Click here Non-Small Cell Lung Cancer Market Drivers and Barriers @ https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Non-Small Cell Lung Cancer Market Research Report
• Coverage- 7MM
• Non-Small Cell Lung Cancer Companies- BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, Abbvie, Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, and others.
• Non-small cell lung cancer Pipeline Therapies- INBRX-106, Datopotamab deruxtecan, Bintrafusp alfa, Patritumab deruxtecan, GB 1211, BBP 398, Cofetuzumab pelidotin, Abemaciclib, BNT 116, JMT101, RMC-4630, MGY 825, Adagrasib, JDQ443, TGRX 326, CKD 702, Citarinostat, IBI 110, XZP 3621, BAY 2927088, SRF388, ABBV 514, Gentuximab injection, Befotertinib, Geptanolimab, Naporafenib, IMU-201, Binimetinib, HS 10241, APX005M, Finotonlimab, Encorafenib, Autologous tumour infiltrating lymphocytes, and others.
• Non-small cell lung cancer Market Dynamics: Non-small Cell Lung Cancer Market Drivers and Barriers

Table of Content
1. Key Insights
2. Non-Small Cell Lung Cancer Executive Summary
3. Non-Small Cell Lung Cancer Competitive Intelligence Analysis
4. Non-Small Cell Lung Cancer: Market Overview at a Glance
5. Non-Small Cell Lung Cancer: Disease Background and Overview
6. Patient Journey
7. Non-Small Cell Lung Cancer Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Non-Small Cell Lung Cancer Unmet Needs
10. Key Endpoints of Non-Small Cell Lung Cancer Treatment
11. Non-Small Cell Lung Cancer Marketed Products
12. Non-Small Cell Lung Cancer Emerging Therapies
13. Non-Small Cell Lung Cancer: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Non-Small Cell Lung Cancer Market Outlook
16. Access and Reimbursement Overview of Non-Small Cell Lung Cancer
17. KOL Views
18. Non-Small Cell Lung Cancer Market Drivers
19. Non-Small Cell Lung Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Get to know more information of the Non-Small Cell Lung Cancer Market Unmet Needs, Non-Small Cell Lung Cancer Market Drivers, Non-Small Cell Lung Cancer Market Barriers, Non-Small Cell Lung Cancer Emerging Therapies @ https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.